Fig. 4

Tumors with SETD2 deleterious mutations exhibit an inflamed immune microenvironment. A Different fractions of seven types of immune cells estimated by the CIBERSORT deconvolution algorithm between SETD2 deleterious mutation and SETD2 non-deleterious mutation groups. Samples were taken from patients across seven types of cancer in the TCGA cohort (bladder urinary cancer, colorectal adenocarcinoma, renal carcinoma, NSCLC, skin cutaneous melanoma, stomach adenocarcinoma, and endometrial carcinoma) (N = 2360). B Comparison of the expression of immune-related gene profiles between the SETD2 non-deleterious mutation group and the deleterious mutation group. Samples were taken from patients across seven cancer types in the TCGA cohort (bladder urinary cancer, colorectal adenocarcinoma, renal carcinoma, NSCLC, skin cutaneous melanoma, stomach adenocarcinoma, and endometrial carcinoma)